Mahato Binod, Nigoskar Shreya, Lakshmi Lingidi Jhansi, Zephy Doddigarla
Department of Biochemistry, Index Medical College, Hospital & Research Centre, Malwanchal University, Indore, IND.
Department of Biochemistry, Hi-Tech Medical College & Hospital, Rourkela, IND.
Cureus. 2024 Aug 29;16(8):e68122. doi: 10.7759/cureus.68122. eCollection 2024 Aug.
Background This research examined the relationship between C-reactive protein (CRP) levels and lymphocyte counts in individuals with chronic obstructive pulmonary disease (COPD) comparing those with metabolic syndrome (MetS) to those without. Methodology This cross-sectional study involved 100 consecutive COPD patients attending the outpatient wards at the Department of Medicine, Index Medical College, over 18 months. MetS was assessed using the International Diabetes Federation's guidelines. Pulmonary function tests such as spirometry were conducted following the European Respiratory Society's procedures, including measurements of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio. The Global Initiative for Obstructive Lung Disease criteria were employed to evaluate COPD severity using post-bronchodilator FEV1. Results Our results indicated no significant differences in demographics, anthropometrics, or pulmonary function tests between COPD patients with MetS and those without. Average age, height, weight, body mass index, and blood pressure readings were similar between the groups, with no significant variations (p > 0.05). However, the total white blood cell count was significantly higher in the MetS group (9,214 ± 3,161.8 cells/µL) compared to the non-MetS group (6,657.8 ± 4,218 cells/µL, p = 0.001). CRP levels were markedly elevated in 90.9% of MetS patients compared to 21.4% of non-MetS patients. Pulmonary function tests showed no significant differences in pre- and post-bronchodilator FEV1 or FEV1/FVC ratios (p > 0.05). Conclusions The study found that individuals with COPD and MetS have elevated levels of CRP, suggesting that this association exacerbates systemic inflammation and metabolic issues. Furthermore, the risk of MetS in COPD patients did not significantly differ between smokers and non-smokers, indicating that MetS can affect all COPD patients regardless of smoking status. Additionally, more than half of the COPD patients had hypertension, a common comorbidity that reflects the oxidative stress and inflammatory processes shared by both conditions.
背景 本研究调查了慢性阻塞性肺疾病（COPD）患者中C反应蛋白（CRP）水平与淋巴细胞计数之间的关系，比较了患有代谢综合征（MetS）的患者和未患代谢综合征的患者。方法 这项横断面研究纳入了18个月内连续就诊于Index医学院内科门诊病房的100例COPD患者。采用国际糖尿病联盟的指南评估代谢综合征。按照欧洲呼吸学会的程序进行肺功能测试，如肺活量测定，包括测量一秒用力呼气容积（FEV1）、用力肺活量（FVC）以及FEV1/FVC比值。采用慢性阻塞性肺疾病全球倡议标准，使用支气管扩张剂后FEV1评估COPD严重程度。结果 我们的结果表明，患有代谢综合征的COPD患者和未患代谢综合征的患者在人口统计学、人体测量学或肺功能测试方面没有显著差异。两组之间的平均年龄、身高、体重、体重指数和血压读数相似，无显著差异（p>0.05）。然而，代谢综合征组的白细胞总数（9214±3161.8个/微升）显著高于非代谢综合征组（6657.8±4218个/微升，p=0.001）。90.9%的代谢综合征患者CRP水平显著升高，而非代谢综合征患者中这一比例为2
